{"id":608164,"date":"2024-06-07T14:52:34","date_gmt":"2024-06-07T18:52:34","guid":{"rendered":"https:\/\/platohealth.ai\/glp-1-treatment-displays-best-in-class-potential-for-mash\/"},"modified":"2024-06-07T15:41:09","modified_gmt":"2024-06-07T19:41:09","slug":"glp-1-treatment-displays-best-in-class-potential-for-mash","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/glp-1-treatment-displays-best-in-class-potential-for-mash\/","title":{"rendered":"GLP-1 treatment displays best-in-class potential for MASH","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
These results from the Phase II trial could lead to clinically meaningful benefits for cardiovascular, renal, and metabolic diseases, Boehringer Ingelheim suggests.<\/p>\n<\/div>\n
New sub-analysis data from a Phase II clinical trial<\/a> show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH). This is compared to 18.2 percent with placebo.<\/p>\n With its novel mechanism of action, the glucagon\/GLP-1 receptor dual agonist<\/a> is the first to show this level of fibrosis benefit in a Phase II MASH trial following 48 weeks of treatment, according to Boehringer Ingelheim.<\/p>\n Results presented at European Association for the Study of the Liver Congress (EASL) 2024 revealed that after 48 weeks of treatment:<\/strong><\/p>\n Actual treatment results revealed up to 87.0 percent of adults achieved at least a 30 percent relative reduction in liver fat. This was compared to 19.7 percent for those given placebo. A relative reduction in liver fat content of up to 64.3 percent was seen in patients treated with survodutide, versus 7.3 percent with placebo.<\/p>\n Moreover, up to 64.5 percent of adults with moderate to advanced fibrosis were able to gain improvement in scarring without worsening of MASH, versus 25.9 percent with placebo.<\/p>\n Secondary endpoint results demonstrated up to 52.3 percent of patients with stages F1, F2 and F3 achieved a significant improvement in fibrosis. This is compared to 25.8 percent with placebo.<\/p>\n Boehringer reveals major data from liver disease trial<\/a><\/p>\n<\/blockquote>\n \u201cbreakthrough [findings] further reinforce survodutide\u2019s potential as a best-in-class treatment for people living with MASH. We will advance quickly into Phase III trials\u201d<\/p>\n<\/div>\n According to the Head of Human Pharma at Boehringer Ingelheim, Carinne Brouillon<\/a>, these \u201cbreakthrough [findings] further reinforce survodutide\u2019s potential as a best-in-class treatment for people living with MASH. We will advance quickly into Phase III trials\u201d.<\/p>\n These results \u201cdemonstrate the potential for glucagon agonism, in addition to GLP-1, to both improve MASH and shift the needle on fibrosis,\u201d shared Dr Arun Sanyal<\/a>, Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine, and Principal Investigator of the trial. \u201cThese data position survodutide as a leading glucagon\/GLP-1 receptor dual agonist that could be a game-changer for people living with MASH and clinically significant fibrosis.\u201d <\/p>\n The full trial results were also published in The New England Journal of Medicine<\/a><\/em>.<\/p>\n Boehringer Ingelheim noted that having licensed survodutide from Zealand Pharma, it is solely responsible for developing and commercialising the treatment worldwide.<\/p>\n These results from the Phase II trial could lead to clinically meaningful benefits for cardiovascular, renal, and metabolic diseases, Boehringer Ingelheim suggests. New sub-analysis data from a Phase II clinical trial show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH). This […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":608167,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/608164"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=608164"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/608164\/revisions"}],"predecessor-version":[{"id":608166,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/608164\/revisions\/608166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/608167"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=608164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=608164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=608164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Potential of survodutide<\/h2>\n
\n
\n